Colon and rectal cancer: An emergent public health problem

doi:10.3748/wjg.v30.i7.644

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1287)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

991

Figures (1-3)

Tables (1-1)

Sum=1115

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=103

Feb 21, 2024 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Feb 21, 2024; 30(7): 644-651
Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.644

Open in New Tab Full Size Figure Download Figure

Figure 1 Progression of colon and rectal cancer pathology.

Open in New Tab Full Size Figure Download Figure

Figure 2 List of modifiable and non-modifiable determinants for colon and rectal cancer.

Open in New Tab Full Size Figure Download Figure

Figure 3 First-line treatment for metastatic colon and rectal cancer patients. anti-EGFR: Anti-epidermal growth factor receptor agent; dMMR/MSI-H: Deficient mismatch repair/microsatellite instability; FOLFOX: 5-fluorouracil + oxaliplatin; FOLFOXIRI: 5-fluorouracil + oxaliplatin + irinotecan; FOLFIRI: 5-fluorouracil + irinotecan; mut: Mutant; XELOX: Capecitabine + oxaliplatin; wt: Wild-type; BRAF: B-raf proto-oncogene.

Citation: Pinheiro M, Moreira DN, Ghidini M. Colon and rectal cancer: An emergent public health problem. World J Gastroenterol 2024; 30(7): 644-651
URL: https://www.wjgnet.com/1007-9327/full/v30/i7/644.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i7.644